Teva Neuroscience, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., markets COPAXONE® (glatiramer acetate injection) and AZILECT® (rasagiline tablets).
Teva Neuroscience offers a total approach to disease management and has established several innovative and effective patient education and advocacy programs. These include Shared Solutions® (1-800-887-8100), a premier support program for MS patients and online support at SharedSolutions.com.
Teva Neuroscience has forged strong partnerships with neurologists and professional organizations (e.g., the American Academy of Neurology (AAN), the International Organization of MS Nurses (IOMSN), Women Neurologists' MS Initiative (WNMSI), the National MS Society (NMSS), and the Parkinson’s Foundation), and is dedicated to supporting and improving the lives of individuals with neurological disorders.
COPAXONE®
COPAXONE® is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Important Safety Information About COPAXONE®
The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These reactions are usually mild and seldom require professional treatment. Patients should tell their doctor about any side effects.
Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems.
A permanent indentation under the skin at the injection site may occur, due to a local destruction of fat tissue. Patients should follow proper injection technique and inform their doctor of any skin changes.
After injecting COPAXONE®, patients should call their doctor right away if they develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, severe pain at the injection site or other uncomfortable changes in their general health. Patients should not give themselves any more injections until their doctor tells them to begin again.
COPAXONE® Prescribing Information
AZILECT®
AZILECT® is indicated for the treatment of the signs and symptoms of Parkinson’s disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.
Important Safety Information About AZILECT
Patients should not take AZILECT if they are taking meperidine as it could result in a serious reaction such as coma or death. Also, patients should not take AZILECT with tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, or cyclobenzaprine. Patients also should not take AZILECT with other monoamine oxidase inhibitors (MAOIs).
Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. If patients have moderate to severe liver disease, they should not take AZILECT. Patients should not exceed a dose of 1 mg per day of AZILECT in order to prevent a possibly dangerous increase in blood pressure. All PD patients should be monitored for melanoma (skin cancer) on a regular basis.
Side effects seen with AZILECT alone are flu syndrome, joint pain, depression, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesia), accidental injury, weight loss, low blood pressure when standing, vomiting, anorexia, joint pain, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.
AZILECT Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
101502